Page last updated: 2024-12-07

sr 48968

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104974
CHEMBL ID308148
SCHEMBL ID185911
MeSH IDM0199524

Synonyms (41)

Synonym
142001-63-6
sr 48,968
gtpl2111
sr-48,968
sr-489686
sr-48968
sr-48965
saredutant
sr 48968c
n-((s)-beta-(2-(4-acetamido-4-phenylpiperidino)ethyl)-3,4-dichlorophenethyl)-n-methylbenzamide
(s)-n-methyl-n(4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl)benzamide
benzamide, n-(4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-n-methyl-, (s)-
sr 48968
benzamide, n-((2s)-4-(4-(acetylamino)-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl)-n-methyl-
PDSP2_000650
PDSP1_000659
sr48968
CHEMBL308148 ,
n-[(s)-4-(4-acetylamino-4-phenyl-piperidin-1-yl)-2-(3,4-dichloro-phenyl)-butyl]-n-methyl-benzamide
n-[(r)-4-(4-acetylamino-4-phenyl-piperidin-1-yl)-2-(3,4-dichloro-phenyl)-butyl]-n-methyl-benzamide
bdbm50071484
n-[(2s)-4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-n-methylbenzamide
720u2qk8i5 ,
saredutant [inn]
unii-720u2qk8i5
[3h]saredutant
[3h]sr48,968
[3h]-sr49868
[3h]sr48968
gtpl3481
saredutant [who-dd]
SCHEMBL185911
DTXSID00161923
CS-0026895
HY-106910
Q3473757
(s)-n-(4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl)-n-methylbenzamide
DB06660
sr 48968; sr 48968c
MS-30095
AKOS040742611

Research Excerpts

Overview

SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

ExcerptReferenceRelevance
"SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. "( A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.
Advenier, C; Brelière, JC; Emonds-Alt, X; Goulaouic, P; Le Fur, G; Naline, E; Neliat, G; Proietto, V; Van Broeck, D; Vilain, P, 1992
)
1.73

Treatment

ExcerptReferenceRelevance
"Pretreatment with SR 48968 (0.3-3 mg/kg, po) in the presence of an NK(1)antagonist dose of CP 99994 (10 mg/kg, po) inhibited the NKA-induced bronchospasm."( Combined NK(1)and NK(2)receptor antagonists on the bronchoconstrictor response to NKA in dogs.
Chapman, RW; Kreutner, W; Nardo, C; Ng, K; Schilling, A; Young, S, 1999
)
0.63

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages."( Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Brawner, ME; Elshourbagy, NA; Foley, JJ; Giardina, GA; Griswold, DE; Hay, DW; Martin, LD; Medhurst, AD; Potts, W; Sarau, HM; Schmidt, DB; Webb, EF, 1997
)
0.3
"We attempted to establish and validate an in vivo pharmacodynamic (PD) rabbit model to screen tachykinin NK(2) receptor (NK(2)-R) antagonists using pharmacological and pharmacokinetic (PK)/PD analyses."( Establishment and validation of a rabbit model for in vivo pharmacodynamic screening of tachykinin NK2 antagonists.
Fujioka, Y; Imanishi, A; Inatomi, N; Kamiguchi, H; Kawamoto, M; Matsumoto-Okano, S; Miura, K; Nishikawa, Y; Tanaka, T; Tsukimi, Y; Yamaguchi, M, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic evaluation of SB 223412 in rat and dog indicated low plasma clearance, oral bioavailability and high and sustained plasma concentrations after 4 to 8 mg/kg oral dosages."( Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
Brawner, ME; Elshourbagy, NA; Foley, JJ; Giardina, GA; Griswold, DE; Hay, DW; Martin, LD; Medhurst, AD; Potts, W; Sarau, HM; Schmidt, DB; Webb, EF, 1997
)
0.3

Dosage Studied

SR 48968C, administrated orally once-daily in a dosage of 100 mg during 9 days, had no effect on airway responsiveness to adenosine 5'-monophosphate.

ExcerptRelevanceReference
" SR 48968 (10(-6) M shifted the [Pro9]SP dose-response curve but did not modify the septide dose-response curve."( Involvement of septide-sensitive tachykinin receptors in inositol phospholipid hydrolysis in the rat urinary bladder.
Beaujouan, JC; Glowinski, J; Saffroy, M; Torrens, Y, 1995
)
1.2
" Thus, we have compared the actions of the selective neurokinin 1 (NK1) (CP-99,994) and neurokinin 2 (NK2) (SR-48,968) receptor antagonists against dose-response curves (DRC) induced by intravenously administered substance P (SP), neurokinin A (NKA), neurokinin B (NKB), beta Ala8-NKA (4-10),Sar9-Met(O2)11SP, and single dose (intravenous) challenge with resiniferatoxin (RTX), a capsaicin-like sensory neurotoxin, leukotriene D4 (LTD4) and antigen."( NK1 and NK2 receptors mediate tachykinin and resiniferatoxin-induced bronchospasm in guinea pigs.
Champion, E; Foulon, DM; Jones, TR; Masson, P; Rodger, IW, 1993
)
0.29
" The NK1 antagonist (+/-)-CP96345 was found to cause, at a maximally tolerated dose of 9 mumol/kg, an approximate 10-fold rightward shift of the dose-response curves for selective NK1 agonists substance P (SP), [Sar9,Met(O2)11]SP and Ac-[Arg6,Sar9,Met(O2)11]SP6-11 without altering responses to selective NK2 agonists neurokinin A (NKA), [Nle10]NKA4-10 or [beta-Ala8]NKA4-10."( Differential blockade by tachykinin NK1 and NK2 receptor antagonists of bronchoconstriction induced by direct-acting agonists and the indirect-acting mimetics capsaicin, serotonin and 2-methyl-serotonin in the anesthetized guinea pig.
Buckner, CK; Campbell, J; Dea, D; Krell, RD; Lengel, D; Liberati, N; Miller, S; Shenvi, A; Stinson-Fisher, C, 1993
)
0.29
" Conversely, SR-48,968 antagonized the bronchoconstrictor response to Nle10-NKA[4-10], right-shifting the dose-response curve by 2 log units, but had no effect on Sar9, Met(O2)11-SP-induced bronchoconstriction."( Tachykinin receptor antagonists inhibit hyperpnea-induced bronchoconstriction in guinea pigs.
Alger, LE; Garland, A; Gitter, B; Howbert, JJ; Jordan, JE; Kao, BM; Leff, AR; Necheles, J; Rodger, IW; Solway, J, 1993
)
0.29
" Airway hyperresponsiveness was evidenced by significant shifts to the left of dose-response curves for intravenous acetylcholine (ACh) without a change in maximum responses to ACh."( The tachykinin NK2 receptor antagonist SR 48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs.
Advenier, C; Emonds-Alt, X; Girard, V; Yavo, JC, 1996
)
0.56
" Guinea-pigs were dosed subcutaneously (s."( Central antitussive activity of the NK1 and NK2 tachykinin receptor antagonists, CP-99,994 and SR 48968, in the guinea-pig and cat.
Bolser, DC; DeGennaro, FC; Hey, JA; McLeod, RL; O'Reilly, S, 1997
)
0.52
" In a placebo-controlled cross-over study, we investigated the effect of SR 48968C, administrated orally once-daily in a dosage of 100 mg during 9 days, on airway responsiveness to adenosine 5'-monophosphate (AMP) in 12 allergic asthmatic patients."( The NK-2 receptor antagonist SR 48968C does not improve adenosine hyperresponsiveness and airway obstruction in allergic asthma.
Kraan, J; Postma, DS; Vink-Klooster, H, 2001
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-K receptorBos taurus (cattle)Ki0.00050.00050.00050.0005AID238675
Substance-K receptorHomo sapiens (human)IC50 (µMol)0.00010.00013.12109.5530AID145472
Substance-K receptorHomo sapiens (human)Ki0.00050.00011.92429.7930AID211724
Substance-P receptorHomo sapiens (human)IC50 (µMol)0.80000.00000.09526.8130AID147677
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
tachykinin receptor signaling pathwaySubstance-K receptorBos taurus (cattle)
regulation of uterine smooth muscle contractionSubstance-K receptorBos taurus (cattle)
muscle contractionSubstance-K receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-K receptorHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionSubstance-K receptorHomo sapiens (human)
intestine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionSubstance-K receptorHomo sapiens (human)
operant conditioningSubstance-K receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-K receptorHomo sapiens (human)
positive regulation of monoatomic ion transportSubstance-K receptorHomo sapiens (human)
positive regulation of smooth muscle contractionSubstance-K receptorHomo sapiens (human)
response to electrical stimulusSubstance-K receptorHomo sapiens (human)
prolactin secretionSubstance-K receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-K receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-K receptorHomo sapiens (human)
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
tachykinin receptor activitySubstance-K receptorHomo sapiens (human)
protein bindingSubstance-K receptorHomo sapiens (human)
substance K receptor activitySubstance-K receptorHomo sapiens (human)
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
sperm headSubstance-K receptorBos taurus (cattle)
plasma membraneSubstance-K receptorHomo sapiens (human)
sperm flagellumSubstance-K receptorHomo sapiens (human)
sperm headSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
sperm midpieceSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-K receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID211901Binding constant towards Tachykinin receptor 2 using BANK as agonist on rabbit pulmonary artery tissues.2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Discovery of novel, orally active dual NK1/NK2 antagonists.
AID211724Binding affinity towards Tachykinin receptor 2 in CHO cells using [3H]-neurokinin A as radioligand2000Bioorganic & medicinal chemistry letters, Oct-16, Volume: 10, Issue:20
The design and synthesis of novel NK1/NK2 dual antagonists.
AID239891Antagonistic activity against Tachykinin receptor 2 binding to [b-Ala8] NKA(4-10) in isolated guinea pig trachea2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Design and synthesis of substituted N-methylbenzamide analogues derived from SR 48,968 as neurokinin-2 receptor antagonists.
AID145472Inhibition of cloned human NK2 (Neurokinin 2) receptor, stably expressed in chinese hamster ovary (CHO) cells was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
L-tryptophan urea amides as NK1/NK2 dual antagonists.
AID238675Binding affinity against bovine Tachykinin receptor 22004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
Design and synthesis of substituted N-methylbenzamide analogues derived from SR 48,968 as neurokinin-2 receptor antagonists.
AID211330Binding constant towards tachykinin receptor 1 using ASMSP as agonist on rabbit pulmonary artery tissues.2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Discovery of novel, orally active dual NK1/NK2 antagonists.
AID147677Inhibition of cloned human NK1 (Neurokinin 1) receptor, stably expressed in chinese hamster ovary (CHO) cells was determined1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
L-tryptophan urea amides as NK1/NK2 dual antagonists.
AID1346371Human NK2 receptor (Tachykinin receptors)1993Biochemical and biophysical research communications, Mar-31, Volume: 191, Issue:3
Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor.
AID1346386Human NK3 receptor (Tachykinin receptors)1994Biochemical and biophysical research communications, Feb-15, Volume: 198, Issue:3
The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.
AID1346371Human NK2 receptor (Tachykinin receptors)2002European journal of pharmacology, Aug-23, Volume: 450, Issue:2
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
AID1346386Human NK3 receptor (Tachykinin receptors)1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
AID1346386Human NK3 receptor (Tachykinin receptors)2002European journal of pharmacology, Aug-23, Volume: 450, Issue:2
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
AID1346314Rat NK2 receptor (Tachykinin receptors)1992Life sciences, , Volume: 50, Issue:15
A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.
AID1346346Human NK1 receptor (Tachykinin receptors)2002European journal of pharmacology, Aug-23, Volume: 450, Issue:2
SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
AID1346371Human NK2 receptor (Tachykinin receptors)1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
AID1346346Human NK1 receptor (Tachykinin receptors)1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.
AID1346314Rat NK2 receptor (Tachykinin receptors)1994Receptors & channels, , Volume: 2, Issue:4
Expression of rat NK-2 (neurokinin A) receptor in E. coli.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (330)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's196 (59.39)18.2507
2000's116 (35.15)29.6817
2010's17 (5.15)24.3611
2020's1 (0.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.29 (24.57)
Research Supply Index5.83 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.59%)5.53%
Reviews4 (1.18%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other332 (98.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]